| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
24,327 |
20,660 |
$1.87M |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
24,287 |
19,055 |
$1.42M |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
16,896 |
14,616 |
$1.18M |
| 87634 |
|
16,877 |
14,600 |
$972K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
15,605 |
13,488 |
$846K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
7,178 |
6,470 |
$703K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
12,983 |
10,390 |
$675K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
21,475 |
17,888 |
$541K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
13,656 |
11,752 |
$386K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
1,409 |
1,231 |
$367K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
7,738 |
6,866 |
$342K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
4,707 |
4,306 |
$307K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
42,922 |
18,266 |
$231K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
12,971 |
10,388 |
$213K |
| 87581 |
|
6,788 |
5,680 |
$187K |
| 87486 |
|
6,776 |
5,673 |
$187K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
13,619 |
10,918 |
$132K |
| 87481 |
|
1,242 |
1,041 |
$124K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
1,222 |
1,006 |
$62K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
4,635 |
4,063 |
$50K |
| 87631 |
|
631 |
271 |
$36K |
| 87640 |
|
1,318 |
1,115 |
$35K |
| 87653 |
|
1,229 |
1,035 |
$33K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,195 |
1,790 |
$25K |
| 99050 |
|
8,463 |
7,499 |
$24K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,697 |
1,204 |
$23K |
| 87500 |
|
845 |
640 |
$21K |
| 99072 |
|
14,304 |
11,522 |
$8K |
| 87807 |
|
827 |
729 |
$6K |
| 81002 |
|
2,272 |
2,002 |
$5K |
| 99401 |
|
231 |
186 |
$2K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
105 |
78 |
$2K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
100 |
75 |
$2K |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
1,375 |
1,187 |
$2K |
| A7015 |
Aerosol mask, used with dme nebulizer |
1,366 |
1,178 |
$1K |
| 90686 |
|
99 |
99 |
$1K |
| 81025 |
|
181 |
163 |
$1K |
| 99173 |
|
754 |
682 |
$1K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
28 |
25 |
$887.63 |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
89 |
66 |
$857.19 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
318 |
267 |
$655.14 |
| 93000 |
|
63 |
58 |
$606.34 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
15 |
13 |
$568.93 |
| 90619 |
|
21 |
17 |
$556.29 |
| 87541 |
|
14 |
14 |
$500.36 |
| 92551 |
|
57 |
46 |
$287.14 |
| 94760 |
|
600 |
528 |
$273.02 |
| 87529 |
|
20 |
13 |
$249.13 |
| 90715 |
|
12 |
12 |
$246.89 |
| 90713 |
|
24 |
21 |
$229.58 |
| 90707 |
|
18 |
14 |
$199.06 |
| 36415 |
Collection of venous blood by venipuncture |
124 |
109 |
$196.07 |
| 90700 |
|
20 |
17 |
$174.13 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
38 |
25 |
$164.38 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,158 |
1,007 |
$153.86 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
286 |
250 |
$150.32 |
| 90461 |
|
94 |
68 |
$141.66 |
| 90716 |
|
18 |
14 |
$121.00 |
| 87511 |
|
21 |
14 |
$107.37 |
| 99001 |
|
244 |
216 |
$82.76 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
1,187 |
1,029 |
$79.46 |
| 96160 |
|
14 |
12 |
$15.89 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
49 |
25 |
$9.15 |
| H0033 |
Oral medication administration, direct observation |
12 |
12 |
$7.00 |
| S9088 |
Services provided in an urgent care center (list in addition to code for service) |
397 |
286 |
$0.00 |